Richard's first career was as a research scientist (PhD bioinformatics), working in academia and early stage biotech. Following an MBA and a short stint in life-science venture capital investing, he started his second career in strategy consulting and co-founded a $100M+ AI start-up. Richard now combines his skills and knowledge to build AI products and new businesses that will greatly benefit society. Richard holds an MBA from the AGSM in Sydney and Tuck School of Business at Dartmouth College, and a PhD from the National Institute of Medical Research. He is a published author in academic peer-reviewed journals; a founding partner of a drug discovery start-up and a fitness studio; and a budding photographer and artist. See full bio.
Faethm's AI SaaS platform models the evolution of work brought about by the disruptive effects of emerging technology. Faethm helps governments and companies prepare their workforce for the future. Richard was co-founder and Chief Data Scientist. Faethm AI (acquired by Pearson Plc in 2021)
Aiquist helps business leaders understand their economic, environmental and societal impact through the power of AI (now closed).
MMH is an IoT-AI start-up providing situational awareness to allow individuals to regain their independence and have confidence in at-home care. Richard is a strategic advisor to, and investor in, MMH (in stealth mode).
Orphan AI is a drug-discovery biotech for the development of novel therapeutics to address genetic diseases. Based on Richard's research and proprietary IP. Richard is the founder of Orphan AI (activities paused).
The best high intensity interval training in Sydney. Closed 2014.
Awards
Fellowships
Degrees
Evolution of work:
Drug and drug target identification:
Protein folding: